SanofiSynthlabo News

Intelliject Inc., a Richmond-based company that developed a device for treatment of severe allergic reactions, said Tuesday it has received a $15 million loan to help it create a pipeline of new products.

This is a continuation of my previous article on biotechnology stocks to watch ahead of ASCO 2012.

Sanofi-Aventis plans to begin testing a novel compound that is designed to starve liver cancer to death in a phase one human clinical trial in China and possibly South Korea in 2013.

Arizona lawmakers are hoping a newly enacted tweak in the state's public records law leads to a new influx of companies willing to pay state universities to do research for them.

A scientist for the French firm Sanofi-Aventis, which made and marketed the blood-thinner with Bristol-Myers Squibb.

BUYINS.NET: Market Maker Surveillance Report. LOW, LUK, SNY, ARMH, GEN, QQQ, Bearishly Biased Price Friction For Thursday, May 17th 2012 BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday.

McDonald's Corp. affirms a report in China Daily that says it increased the four different products by 1 yuan , at the end of April, marking the second price bump so far this year.

Sanofi-Aventis opened at 35.92 on Thursday. Sanofi-Aventis has a 52-week low of $30.98 and a 52-week high of $40.58. The company has a market cap of $95.098 billion and a price-to-earnings ratio of 11.62. SNY has been the subject of a number of other recent research reports.

Based in New Haven, CT, Rib-X Pharmaceuticals scheduled a $75 million IPO with a market capitalization of $204 million at a price range mid-point of $13 for Wednesday, May 9, 2012.

Sanofi has begun the phased process of laying off workers at its Kansas City manufacturing plant and expects to completely close the operation by the August of 2016, four years later than originally expected.

Sanofi-Aventis' headquarters in Paris. A former worker at the drug maker's U.S. headquarters in Bridgewater was sentenced today to 18 months in prison for stealing company trade secrets.

The company manufactures its products in the areas of thrombosis, central nervous system disorders, diabetes, vaccines, oncology, cardiovascular diseases, and internal medicine, as well as neurodegenerative diseases, metabolic disorders, allergies and infectious diseases.

Thank you for your interest in the Supv Quality Control. To begin the application process, please enter your email address.

's stock had its "neutral" rating restated by Zacks in a report issued on Tuesday.

April 29--Trading in shares of Protalix Biotherapeutics Inc. has been heavy in recent weeks, ahead of a decision by US Food and Drug Administration whether to approve the company's treatment for Gaucher's disease Uplyso.